EP
KRYS icon

Essential Partners’s Krystal Biotech KRYS Stock Holding History

Essential Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.33K Hold
4
– – ﹤0.01% 2083
2026
Q2 		$1.49K Hold
4
– – ﹤0.01% 2088
2026
Q1 		$1.03K Hold
4
– – ﹤0.01% 2239
2025
Q4 		$986 Hold
4
– – ﹤0.01% 2034
2025
Q3 		$706 Buy
4
+3
+300% +$449 ﹤0.01% 2119
2025
Q2 		$137 Buy
+1
New +$147 ﹤0.01% 2026

Other funds holding KRYS

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
TNAM
Terra Nova Asset Management New York $155M AUM 33.52% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return

Essential Partners's KRYS Position: Q3 2026 in Review

Essential Partners held its Krystal Biotech (KRYS) position steady in Q3 2026 at 4 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Essential Partners first reported a position in KRYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.49K in Q2 2026. 27 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Essential Partners held 4 shares of Krystal Biotech worth $1.33K as of Q3 2026.
  • Essential Partners left its Krystal Biotech share count unchanged in Q3 2026.
  • Krystal Biotech made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2083 holding.
  • Essential Partners first reported a position in Krystal Biotech in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Krystal Biotech position peaked at $1.49K in Q2 2026.
  • 27 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.